Videos

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.

Mikkael A. Sekeres MD, MS, discusses transfusion independence rates with imetelstat in patients with low- to intermediate-1 risk myelodysplastic syndromes.

Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses the artificial intelligence (AI) technology that is currently being used at his institution.

Aakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.

Sangeetha Venugopal, MD, MS, discusses what she is most interested about regarding unmet needs in patients with AML.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.

Sangeetha Venugopal, MD, MS, discusses the evolving field of acute myeloid leukemia treatment.

Claire Saxton, MBA, discusses a study on the concept of social toxicity in patients with acute myeloid leukemia.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.

Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.

Medical experts examine the case of a 61-year-old male patient with a history of low-volume, indolent metastatic clear cell renal cell carcinoma, who has undergone left nephrectomy and adrenalectomy.

Adrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Medical experts explore how improved hemoglobin levels with luspatercept treatment impact overall well-being and daily functioning, with insights from the post-hoc analysis of the COMMANDS study revealing relationships between hemoglobin levels and quality of life.

Medical experts examine the role of luspatercept as a first-line treatment for anemia in lower-risk MDS patients, including those with RS+/RS- and serum EPO ≤200 mU/L, and discuss its efficacy and potential benefits for this population.

Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.

Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Bhavana Pothuri, MD, discusses the biggest unmet needs for patients with endometrial cancer.

Aman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.

Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.

Mikkael A. Sekeres MD, MS, discusses the primary differences between imetelstat and other treatments available for patients with low- to intermediate-1 risk myelodysplastic syndromes.

Meredith McKean, MD, discusses a novel mRNA therapy for the treatment of solid tumors.

Nausheen Ahmed, MD, discusses the guidelines for monitoring patients after receiving CAR T-cell therapy.